Neurology · AnticonvulsantRegulatory Approvalregulatorymid-term

Teva Pharmaceuticals Receives AP Status for Gabapentin Supplement

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Teva25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 12:32:56 PM

Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Teva Pharmaceuticals' receipt of Abbreviated Approval for a gabapentin supplement is significant as it may strengthen their market position and influence competitive dynamics. This development necessitates close monitoring of market responses and potential shifts in pricing strategies among competitors. Regulatory context from FDA (FDA AP — GABAPENTIN (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (13 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for gabapentin formulations. The strongest clinical anchor is The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Anticonvulsant, 8 regulatory and 5 competitive items passed relevance filtering for Teva.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Supplemental Application for BRILINTA (Ticagrelor) (Humanexa Signals) — sponsor/company relevance (astrazeneca). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval may enhance Teva's position in the gabapentin market, potentially impacting competitors with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GABAPENTIN (SUPPL) (FDA). Entity match (gabapentin). The Abbreviated Approval indicates compliance with regulatory standards, but it also opens the door for potential challenges from competitors regarding market access and product positioning.

Key Risks

Elevated medium regulatory exposure for Teva could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development) could weigh on Teva through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The approval could lead to increased market share for Teva, affecting revenue projections for competitors with similar gabapentin products. Companies may need to adjust their pricing strategies to remain competitive.
Upside for Teva may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for gabapentin formulations.

What Would Change This Assessment

This becomes more urgent if Monitor for any market entry timelines and competitor responses following this approval.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (teva)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (teva)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source
FDA AP — GABAPENTIN (SUPPL)
FDAhigh relevance
Entity match (gabapentin)
FDA document
View source

The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Robotic Minimally Invasive Inguinal Hernia Repair Post-Market Clinical Study With the DEXTER Robotic System
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Post-marketing Observational Study of Oral Cholera Vaccine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GT
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Supplemental Application for BRILINTA (Ticagrelor)
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Supplemental Application for Wegovy (Semaglutide)
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teva
Gabapentin
Competitors in the anticonvulsant market

Commercial impact

medium

The approval could lead to increased market share for Teva, affecting revenue projections for competitors with similar gabapentin products. Companies may need to adjust their pricing strategies to remain competitive.

Regulatory impact

medium

The Abbreviated Approval indicates compliance with regulatory standards, but it also opens the door for potential challenges from competitors regarding market access and product positioning.

What to watch

Monitor for any market entry timelines and competitor responses following this approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.